Sichuan Kelun Pharmaceutical (002422.SZ): The research results of Lukan satuzumab monoclonal antibody (sac-TMT) will be announced at the 2025 European Lung Cancer Congress.

date
22:22 18/03/2026
avatar
GMT Eight
Koron Pharmaceuticals (002422.SZ) announced that the final analysis results of the overall survival (OS) of the key clinical study (OptiTROP-Lung03) of its subsidiary Sichuan Koronbote Bio Pharmaceutical Co., Ltd. (referred to as "Koronbote") targeting human trophoblast cell surface antigen 2 (TROP2) antibody-drug conjugate (ADC) sacituzumab govitecan (sac-TMT) (Seitai Lai) will be presented in a small oral report session at the 2026 European Lung Cancer Conference (ELCC) in Copenhagen, Denmark from March 25th to 28th.
Sichuan Kelun Pharmaceutical (002422.SZ) announced that its controlling subsidiary Sichuan Kelun Botai Biopharmaceutical Co., Ltd. ("Kelun Botai")'s target cell surface antigen 2 (TROP2) antibody drug conjugate (ADC) sacituzumab govitecan (sac-TMT) (Jia Tailai) key clinical study (OptiTROP-Lung03) final analysis of overall survival (OS) results will be presented in a small oral report session at the 2026 European Lung Cancer Conference (ELCC) held in Copenhagen, Denmark from March 25th to 28th. The study results have successfully been selected for a breakthrough abstract presentation (report number: LBA4) and the related abstract has been published in the ESMOOPEN journal.